Curis, Inc. (CRIS) Presents at Cantor Global Healthcare Conference

Company Overview - Curis is at an exciting crossroads with a focus on one primary drug, an IRAK4 and FLT3 inhibitor, which is being developed for Non-Hodgkin Lymphoma (NHL) and Acute Myeloid Leukemia (AML) [3] - The company has a promising pipeline and is funding studies for solid tumors, primarily supported by the NIH [3] Drug Development - The drug has shown compelling proof-of-concept data in Primary Central Nervous System Lymphoma (PCNSL) with a study involving 34 patients [3] - The drug is designed to be an add-on therapy to BTK inhibitors, targeting the TLR pathway while BTK inhibitors block the BCR pathway, potentially leading to higher response rates and complete remission in NHL [4]